| Ident. | Authors (with country if any) | Title |
|---|
| 000064 (2017) |
Fabrice Rivollier [France] ; Boris Chaumette [France] ; Narjes Bendjemaa [France] ; Mélanie Chayet [France] ; Bruno Millet [France] ; Nematollah Jaafari [France] ; Amina Barhdadi [Canada] ; Louis-Philippe Lemieux Perreault [Canada] ; Sylvie Provost [Canada] ; Marie-Pierre Dubé [Canada] ; Raphaël Gaillard [France] ; Marie-Odile Krebs [France] ; Oussama Kebir [France] | Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol |
| 000087 (2017) |
Kyle John Wilby [Qatar] ; Eric G. Johnson [États-Unis] ; Hannah E. Johnson [États-Unis] ; Mary H H. Ensom [Canada] | Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis. |
| 000183 (2016) |
Daniel Weintraub [États-Unis] ; Helen C. Kales ; Connie Marras [Canada] | The Danger of Not Treating Parkinson Disease Psychosis-Reply. |
| 000219 (2016) |
Philippe Desmarais [Canada] ; Fadi Massoud [Canada] ; Josée Filion [Canada] ; Quoc Dinh Nguyen [Canada] ; Paulina Bajsarowicz [Canada] | Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review. |
| 000224 (2016) |
Anna Chang [Canada] ; Susan H. Fox [Canada] | Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management. |
| 000285 (2016) |
O. Kebir [France] ; B. Chaumette [France] ; F. Rivollier [France] ; F. Miozzo [France] ; L P Lemieux Perreault [Canada] ; A. Barhdadi [Canada] ; S. Provost [Canada] ; M. Plaze [France] ; J. Bourgin [France] ; R. Gaillard [France] ; V. Mezger [France] ; M-P Dubé [Canada] ; M-O Krebs [France] | Methylomic changes during conversion to psychosis |
| 000379 (2016) |
Lucia Ricciardi [Royaume-Uni] ; Kristy J. Espay [États-Unis] ; Robert Krikorian [États-Unis] ; Alfonso Fasano [Canada] ; Alberto J. Espay [États-Unis] | Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease. |
| 000689 (2015) |
Clive Ballard [Royaume-Uni] ; Stuart Isaacson [États-Unis] ; Roger Mills [États-Unis] ; Hilde Williams [États-Unis] ; Anne Corbett [Royaume-Uni] ; Bruce Coate [États-Unis] ; Rajesh Pahwa [États-Unis] ; Olivier Rascol [France] ; David J. Burn [Royaume-Uni] | Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. |
| 000877 (2014) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. |
| 000971 (2014) |
Susan H. Fox [Canada] | Pimavanserin as treatment for Parkinson's disease psychosis. |
| 000C07 (2014) |
JINGYI MA [Canada] ; L. Stan Leung [Canada] | Deep brain stimulation of the medial septum or nucleus accumbens alleviates psychosis-relevant behavior in ketamine-treated rats |
| 000C50 (2013) |
James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. |
| 000E73 (2013) |
Zahinoor Ismail [Canada] ; Chetachi A. Emeremni [États-Unis] ; Patricia R. Houck [États-Unis] ; Sati Mazumdar [États-Unis] ; Jules Rosen [États-Unis] ; Tarek K. Rajji [Canada] ; Bruce G. Pollock [Canada, États-Unis] ; Benoit H. Mulsant [Canada, États-Unis] | A Comparison of the E-BEHAVE-AD, NBRS and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated with Dementia |
| 001038 (2013) |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 001604 (2011) |
M. Hasnain [Canada] | Psychosis in Parkinson's disease: therapeutic options. |
| 002036 (2009) |
Aw Zuardi [Brésil] ; Jas Crippa [Brésil] ; Jec Hallak [Brésil] ; Jp Pinto [Brésil] ; Mhn Chagas [Brésil] ; Ggr Rodrigues [Brésil] ; Sm Dursun [Canada] ; V. Tumas [Brésil] | Cannabidiol for the treatment of psychosis in Parkinson’s disease |
| 002069 (2009) |
Mehrul Hasnain [Canada] ; W. Victor R. Vieweg [États-Unis] ; Mark S. Baron [États-Unis] ; Mary Beatty-Brooks [États-Unis] ; Antony Fernandez [États-Unis] ; Anand K. Pandurangi [États-Unis] | Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism |
| 002230 (2008) |
T R Thomsen [Canada] ; M. Panisset [Canada] ; O. Suchowersky [Canada] ; A. Goodridge [Canada] ; T. Mendis [Canada] ; A E Lang [Canada] | Impact of standard of care for psychosis in Parkinson disease |
| 002613 (2007) |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 002720 (2006) |
J M Miyasaki [Canada] ; K. Shannon ; V. Voon ; B. Ravina ; G. Kleiner-Fisman ; K. Anderson ; L M Shulman ; G. Gronseth ; W J Weiner | Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. |
| 002804 (2006) |
Philip Seeman [Canada] ; Johannes Schwarz [Allemagne] ; Jiang-Fan Chen [États-Unis] ; Henry Szechtman [Canada] ; Melissa Perreault [Canada] ; G. Stanley Mcknight [États-Unis] ; John C. Roder [Canada] ; Rémi Quirion [Canada] ; Patricia Boksa [Canada] ; Lalit K. Srivastava [Canada] ; Kazuhiko Yanai [Japon] ; David Weinshenker [États-Unis] ; Tomiki Sumiyoshi [Japon] | Psychosis pathways converge via D2High dopamine receptors |
